The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed. Phase I CITN-12: Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm. Cancer Immunotherapy Trials Network; Uldrick, Thomas S. (301) 402-6296...
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
